News & Media / Newsroom
Ahead of World Digestive Health 2022, Italian pharmaceutical group Alfasigma is proud to announce the launch of its new diagnostic drug Lumeblue™ (per-oral methylene blue). This latest innovation is part of the company’s commitment to raising awareness on colorectal cancer (CRC), still the second leading cause of cancer deaths worldwide, through a healthy lifestyle and regular screenings.
#LeaveYourMark is back. #LeaveYourMark 2022 goes international sharing thoughts and experiences of Alfasigma colleagues from all over the world online.
Developed by the researchers of Labio 4.0 of Pomezia and University of Rome Tor Vergata, it has been obtained from the blood of doctors of the Hospital of Bergamo infected during the pandemic emergency.
Jean-Christophe Lemaistre, before joining Alfasigma France, has covered different
Among the top 10 also A_MAB in the HR category. To Alfathon goes the Best PR & Communication project.
Together they are worth 12.5 billion in turnover and 44,500 employees: so called Fab13 companies presented 'The social and strategic role of the Italian pharmaceutical industry’
[email protected]
+39.051.6489.562
+39.051.6489.884
+39.06.9139.4396
You’re entering Alfasigma global website
I agree